Dana-Farber Cancer Institute: Glioblastoma trials

The registry lists 14 Glioblastoma studies with Dana-Farber Cancer Institute as lead sponsor. 1 are open to participants now and 7 have results posted.

Phase 1 4Phase 2 9No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Serial MRI Scans During Radiation TherapyRecruitingNCT04188535Not applicable
• VB-111 in Surgically Accessible Recurrent/Progressive GBMTerminatedNCT04406272Phase 2Results posted
• Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent GlioblastomaCompletedNCT03661723Phase 2Results posted
• Mathematical Model-Adapted Radiation In GlioblastomaCompletedNCT03557372Not applicableResults posted
• A Study of Abemaciclib in Recurrent GlioblastomaActive, not recruitingNCT02981940Phase 2Results posted
• Trial of Ponatinib in Patients With Bevacizumab-Refractory GlioblastomaCompletedNCT02478164Phase 2Results posted
• Pembrolizumab +/- Bevacizumab for Recurrent GBMCompletedNCT02337491Phase 2Results posted
• Amgen 386 for Recurrent GlioblastomaCompletedNCT01290263Phase 1/2Results posted
• ASP8374 + Cemiplimab in Recurrent GliomaCompletedNCT04826393Phase 1
• Abemaciclib + Pembrolizumab In GlioblastomaWithdrawnNCT04118036Phase 2
• A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2Active, not recruitingNCT03152318Phase 1
• Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBMActive, not recruitingNCT02287428Phase 1
• Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00165477Phase 2
• Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00047294Phase 2